A phase I trial of an oral subtype-selective histone deacetylase inhibitor chidamide in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer

摘要

Objective This phase I study was to evaluate safety, maximum tolerated dose, pharmacokinetics and preliminary antitumor activity of chidamide, a novel subtype-selective histone deacetylase (HDAC) inhibitor, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).